Zacks.com on MSN1d
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...
Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...
A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...
Zacks.com on MSN1d
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?The market expects Ardelyx (ARDX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
After hours: 7:30:31 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback